Tech Company Financing Transactions

Allozyne Funding Round

Arch Venture Partners participated in a $2.7 million venture round for Allozyne. The round was recorded on 9/30/2009.

Transaction Overview

Company Name
Announced On
9/30/2009
Transaction Type
Venture Equity
Amount
$2,663,000
Round
Undisclosed
Investors

Arch Venture Partners (Carl Weissman)

Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1600 Fairview Ave. East 300
Seattle, WA 98102
USA
Email Address
Overview
Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics.
Profile
Allozyne LinkedIn Company Profile
Social Media
Allozyne Company Twitter Account
Company News
Allozyne News
Facebook
Allozyne on Facebook
YouTube
Allozyne on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Meenu Karson
  Meenu Karson LinkedIn Profile  Meenu Karson Twitter Account  Meenu Karson News  Meenu Karson on Facebook
Chief Scientific Officer
Kenneth Grabstein
  Kenneth Grabstein LinkedIn Profile  Kenneth Grabstein Twitter Account  Kenneth Grabstein News  Kenneth Grabstein on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/30/2009: Ceptaris Therapeutics venture capital transaction
Next: 9/30/2009: Aztek Networks venture capital transaction

 

Share this article

 


Where The Data Comes From

We report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary